COST-EFFECTIVENESS OF CANNABIDIOL ADD-ON THERAPY VERSUS PLACEBO FOR THE TREATMENT OF SEIZURES IN TUBEROUS SCLEROSIS COMPLEX

被引：0
|
作者：
Bowditch, S. [1 ]
Burke, C. [2 ]
Crossan, C. [2 ]
Hemstock, M. [2 ]
Tyas, E. [2 ]
Lee, D. [2 ]
机构：
[1] Jazz Pharmaceut Inc, London, England
[2] Lumanity, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE16
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [1] A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
    Burke, Colin
    Crossan, Catriona
    Tyas, Emma
    Hemstock, Matthew
    Lee, Dawn
    Bowditch, Sally
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (04) : 611 - 626
  • [2] Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex A Placebo-Controlled Randomized Clinical Trial
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Bhathal, Hari
    Jansen, Floor E.
    Kotulska, Katarzyna
    Lawson, John A.
    O'Callaghan, Finbar J.
    Wong, Michael
    Sahebkar, Farhad
    Checketts, Daniel
    Knappertz, Volker
    [J]. JAMA NEUROLOGY, 2021, 78 (03) : 285 - 292
  • [3] Cannabidiol treatment for seizures in tuberous sclerosis complex
    Lattanzi, Simona
    [J]. EPILEPSY & BEHAVIOR, 2022, 132
  • [4] Cost-effectiveness analysis of levetiracetam add-on therapy for the treatment of partial onset seizures: A comparative analysis versus topiramate
    Godfroid, P
    Pimentel, J
    [J]. EPILEPSIA, 2005, 46 : 271 - 272
  • [5] Long-term safety and efficacy of add-on cannabidiol for treatment of seizures associated with tuberous sclerosis complex in an open-label extension
    Kwan, Patrick
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor E.
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    [J]. EPILEPSIA, 2021, 62 : 145 - 146
  • [6] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Aschner, P.
    Garrido Lecca, S.
    Aiello, E.
    Jimenez, C.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
  • [7] Cost-effectiveness of add-on lamotrigine therapy in clinical practice
    Knoester, PD
    Boendermaker, AJ
    Egberts, ACG
    Hekster, YA
    Keyser, A
    Severens, JL
    Renier, WO
    Deckers, CLP
    [J]. EPILEPSY RESEARCH, 2005, 67 (03) : 143 - 151
  • [8] COST-EFFECTIVENESS OF NIASPAN® VERSUS ZETIA® AS ADD-ON TREATMENT TO STATIN THERAPY IN HIGH-RISK PATIENTS
    Sorensen, S., V
    Webb, S. F.
    Burge, R. T.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A393 - A393
  • [9] Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome
    Edward E. Neuberger
    Josh J. Carlson
    David L. Veenstra
    [J]. PharmacoEconomics, 2020, 38 : 1237 - 1245
  • [10] Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome
    Neuberger, Edward E.
    Carlson, Josh J.
    Veenstra, David L.
    [J]. PHARMACOECONOMICS, 2020, 38 (11) : 1237 - 1245
12345